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ABSTRACT  
Silica nanoparticles (SiNPs) are attractive drug delivery platforms and diagnostic 
tools, however, recent reports suggest that they may be detrimental to conduit 
arterial function. We aimed to examine whether SiNPs influence the function of small 
size arteries, which play an essential role in controlling blood perfusion into tissues, 
using an ex vivo model. We show that while exposure to SiNPs under static 
conditions, attenuated dilator responses ex vivo, attenuation was only evident at 
lower agonist concentrations, when exposed under flow conditions or in vivo. 
Pharmacological inhibition studies suggest that SiNPs may interfere with the 
endothelial dependent hyperpolarising factor (EDHF) vasodilator pathway. The 
dosage dependent influence of SiNPs on arterial function will help identify strategies 
for their safe clinical administration. 
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1. INTRODUCTION 
There is a growing interest in the fabrication of silica nanoparticles (SiNPs) for 
applications in cell tracking, imaging diagnostics and medical therapeutics, as drug 
delivery platforms, due to their tuneable size, stability under flow conditions, and its 
ability to decompose into silicic acid (DIACONU et al., 2010) (Kim et al., 2011, 
Motwani et al., 2011, Jokerst et al., 2013, Liberman et al., 2014) [reviewed in 4]. 
However, there are limited studies investigating their influence on blood vessel 
function. The lining endothelial cell (EC) layer displays the first contact surface for 
nanoparticles when intravenously injected for diagnostic and/or therapeutic 
purposes. Furthermore, in vivo inhalation studies have demonstrated the 
translocation of nanoparticles into the systemic circulation, where they can be 
detected in tissues distal to the exposure site (Du et al, year?). A number of studies 
have suggested that SiNPs may be cytotoxic to ECs, depending on their size, shape, 
and interaction with target molecules (Kim et al., 2015).  For example, amorphous 
SiNPs have been shown to induce endothelial dysfunction in human umbilical vein 
ECs (Corbalan et al., 2011) as well as the disruption of vascular homeostasis 
(Corbalan et al., 2012). These effects were mediated via a nitric oxide 
(NO)/peroxynitrite imbalance associated with an increased peroxynitrite (ONOO-) 
production leading to a low [NO]/[ONOO-] ratio (Corbalan et al., 2012) and platelet 
aggregation within the blood stream via adenosine diphosphate and matrix 
metalloproteinase 2-dependent mechanisms respectively. As ECs are key 
modulators of vessel function and contractility, the above studies highlight the need 
to understand the effect of SiNP uptake on the physiological function of vessels. 
 
The effects of nanoparticles on blood vessels can be distinguished in large and small 
blood vessels, due to their varied structural and physiological characteristics and the 
profile of mediators released by the lining ECs. We have previously demonstrated 
that SiNPs of 100 and 200 nm in size have no overall detrimental effect on conduit 
arterial function, but is influenced by nanoparticle charge, dosage and dye 
encapsulation (Akbar et al., 2011, Farooq et al., 2013). The influence of SiNPs on 
the function of small size arteries remains poorly understood, yet this is key to 
establishing SiNP biosafety, as the function of these small arteries is important in the 
regulation of blood perfusion into organs and tissues. The vascular endothelium 
plays an important role in the modulation of vascular tone through the release of 
vasoconstrictor and vasodilator factors. A number of molecules are implicated in 
contributing to the vasodilator response in arteries, including nitric oxide, 
prostanoids, and endothelial derived hyperpolarising factors (EDHFs). EDHFs are 
represented by a number of candidate molecules, including epoxyeicosatrienoic acid 
(EETs), hydrogen peroxide, and potassium ions through the activation of small 
(SKCa) and intermediate (IKCa) conductance calcium-activated potassium channels 
[reviewed in Luksha et al; atherosclerosis, 2009]. While the major dilator component 
is attributed to nitric oxide in conduit size arteries, EDHF is the principal dilator in 
small (~200-300 μm diameter; e.g. second and third-order) mesenteric arteries 
(Hilgers and Webb, 2007). Other components such as nitric oxide and prostanoids 
from the cyclooxygenase pathway (Honing et al., 2000) may have a minor role in 
contributing to small vessel dilation, particularly when EDHF action is compromised. 
The more pronounced role of EDHF in small mesenteric arteries compared with 
medium sized and large conduit arteries such as the superior mesenteric artery and 
the aorta is attributed to the action of intermediate and small conductance calcium-
sensitive potassium channels (IKCa and SKCa), in acetylcholine-induced relaxations 
(Hinton and Langton, 2003, Hilgers et al., 2006).  
 
In rat mesenteric arteries, the stimulation of ECs results in the activation of 
endothelial calcium-sensitive potassium channels and leads to the generation of the 
hyperpolarising event. The resulting efflux of potassium ions (K+) from ECs via SKCa 
and IKCa channels (Edwards et al., 1998), regarded as the hyperpolarisation current, 
propagates or spreads passively via myoendothelial gap junctions (Sandow et al., 
2002) to accumulate in the myoendothelial space where it stimulates the sodium ion 
(Na+)/K+ ATPase pumps and voltage-gated potassium channels (Kv; e.g. Kv1.5 and 
Kv2.1 (Hald et al., 2012)) in vascular smooth muscle cells (VSMCs) (Edwards et al., 
1998). This results in the EDHF-attributed hyperpolarisation in VSMCs. Hence, the 
EC-VSMC electrical coupling (Little et al., 1995) is characterised by endothelial 
potassium channels that influence smooth muscle cell contractile activity by reducing 
Ca2+ influx via voltage-operated Ca2+ channels and by suppression of key enzymes 
involved in agonist-induced transduction pathways (Itoh et al., 1992). The aim of the 
present study was to investigate the influence of SiNPs on small mesenteric arterial 
function, after acute exposure ex vivo, under both static and flow conditions, and 
following intravenous (iv) injection in vivo. Furthermore, to explore the mechanism of 
attenuated dilator responses by SiNPs, inhibition studies were carried out using 
specific pharmacological inhibitors of the various dilator pathways. 
 
 
 
 
2. MATERIALS AND METHODS 
2.1. Chemicals and reagents 
All agonists and reagents were obtained from Sigma (Poole, UK). Physiological salt 
solution (PSS) composition [mM]: 119 NaCl, 4.7 KCl, 1.2 MgSO47H2O, 25 NaHCO3, 
1.17 KHPO4, 0.03 K2EDTA, 5.5 glucose, 1.6 CaCl22H2O; pH 7.4. High potassium 
PSS (KPSS, 60 mM KCl) composition [mM]: 78.2 NaCl, 60 KCl, 1.2 MgSO47H2O, 25 
NaHCO3, 1.17 KHPO4, 0.03 K2EDTA, 5.5 glucose, 1.6 CaCl22H2O; pH 7.4. Water 
purified by Milli-Q purification system was utilised for all studies.  
 
2.2. Synthesis and characterisation of silica nanoparticles 
Mono-dispersed dye-encapsulated fluorescent SiNPs was synthesised using the 
modified Stöber sol-gel method. (Stöber et al., 1968, Ismail et al., 2010). The initial 
stages in the synthesis involved the incorporation of the rhodamine B isothiocyanate 
(RBITC) core within silica. Briefly 40 mg of RBITC was stirred with 600 µL of 3-
aminopropyltrimethoxysilane (APS) at room temperature (~20oC) under nitrogen 
atmosphere for 3 hours. Ammonium hydroxide (NH4OH), absolute ethanol, water 
and TEOS were magnetically stirred for 15 minutes. 50 µL of APS coupled with 
RBITC was added. The reaction solutions were centrifuged at 6000 rpm for 20 
minutes and the supernatant solution discarded; sedimented nanoparticles were re-
dispersed in absolute ethanol by vortex mixing and ultra-sonication. The solution was 
re-centrifuged at 6000 rpm for a further 20 minutes and the supernatant discarded 
again. Nanoparticles were re-dispersed in distilled water and then characterised 
using the Malvern Zeta-sizer and scanning electron microscopy. 
 
2.3. Vascular function studies 
Male Wistar rats (150-250 g) were humanely euthanised in accordance with the 
‘Animals (Scientific Procedures) Act 1986’ and Institutional guidelines. Animals were 
killed by stunning and cervical dislocation of the neck and the mesentery removed 
and placed in ice cold PSS. Small mesenteric arteries (2nd – 3rd order, 145-300 μm 
initial diameter, 3-4 mm in length) were finely dissected (the fat tissue layer and 
connective tissue surrounding each vessel were also removed), isolated and 
mounted between two glass cannulae (tied using fine nylon thread) on a pressure 
myograph chamber (Living Systems, Burington, USA). The mounting of the 
mesenteric artery on a pressure myograph chamber is a very delicate procedure and 
requires extensive practice to avoid any damage to the endothelial cell layer. Two 
knots of thread were tied on both cannulae, which were used to tie the mounted 
vessel and keep it in place. Arteries were initially pressurised to an intravascular 
(luminal) pressure of 60 mmHg and maintained at that pressure using a pressure 
servo-control unit (Living Systems, Burlington, USA); the system tubing and valve 
systems was initially checked for leaks to ensure a sealed pressurised circuit. All 
vessels were constantly superfused in a continuous source of PSS at 37℃, pH 7.4, 
and gassed with 95% O2-5% CO2 (from a standard gas cylinder), with the 
superfusate entering and leaving the chamber via luer connections in the side of the 
chamber. This was done under a Nikon inverted microscope to allow for optimal 
resolution in visualising the tissues. Lumen and internal diameters of the vessel were 
constantly measured using a video dimension analyser, with data recorded on the 
computer using Chartlab 5 software (Powerlab system, AD Instruments, UK) for later 
analysis. Arteries were superfused at the end of each experiment with Ca2+-free PSS 
containing 2 mM EGTA for 20-30 minutes to obtain passive diameters and allow the 
vessel to relax completely. 
 
The viability of the mesenteric arteries was assessed for their ability to constrict to a 
high potassium solution (KPSS, 60 mM KCl). The influence of SiNPs on mesenteric 
arterial function was assessed in response to vasoconstrictors and vasodilators 
before (in non-treated control vessels), and 30 minutes subsequent to intraluminal 
infusion in PSS (control) or SiNPs. The intraluminal infusion was conducted as 
follows: The pressure servo-control unit was turned off and a 1 mL syringe was 
inserted into one end of the 3-way luer connection in the side of the pressure 
myograph chamber. A 0.5 ml of diluted SiNP solution (in PSS) was slowly 
administered via the syringe. The 3-way luer valve was closed off and pressure 
returned to 60 mmHg, using the pressure servo unit. For the flow experiments, 
SiNPs were infused at a flow rate of 10-20 µL/min, over the 30 min incubation period, 
using a microfusion pump connected to the end of one of the glass cannulae. 
Vasoconstrictor responses (phenylephrine [Phe], 10-9-10-4 M) and endothelial-
dependent (acetylcholine [ACh], 10-13-10-3 M) and independent (sodium nitroprusside 
[SNP], 10 and 100 nM and papaverine [PAPA], 100 μM) dilator responses were 
assessed before (initial responses), and 30 minutes subsequent to intralumenal 
infusion of PSS or SiNPs (second responses). The vasodilator responses were 
assessed on vessels that have been precontracted in a submaximal dose of Phe. 
Responses after incubation in PSS were used as controls to compare with SiNPs 
responses. Two dosages of SiNPs were used; high dose (at 5.32 x 1011 NPs/mL), 
and low dose (at 1.01 x 1011 NPs/mL). 
 
2.4. In vivo animal studies 
Animal procedures were conducted in compliance with institutional guidelines and 
UK Home Office requirements (Project License 70/6616). Animals were given food 
and water ad libitum and housed in a 12 hours/12hours light dark cycle. The rat was 
anaesthetised in an induction chamber using 2% isoflurane. Maintenance of 
anaesthesia was achieved by the use of 1.5-2.0% isoflurane via a concentric 
oronasal mask connected to an anaesthetic circuit. Core body temperature was 
maintained at 37.0 ± 0.5oC using a heating pad and a rectal temperature probe. The 
in vivo study involved an intravenous injection of SiNPs at a concentration of 10 
mg/Kg of animal weight into the tail vein of a 300 g unconscious male Wistar rat. For 
this purpose, 3 mg of SiNPs was suspended in 100 µL of PSS and injected into the 
animal. SiNPs were given at the same dosage used in our ex vivo study (5.32 x 1011 
NPs/mL dosage), taking into consideration the blood volume, thus 5.32 x 1011 
NPs/mL of SiNPs per 1 mL of animal blood (0.2 mg/mL). After injection, the rat was 
monitored for a period of 2 hours and then terminated by cardiac catheterisation and 
scarified. At the end of the in vivo experiment, the rat mesentery, and other vessels 
(aortic) were dissected-away and placed in ice-cold PSS. Other tissues such as the 
brain, lung, heart, stomach, liver, spleen, small intestine, large intestine, kidneys, 
bladder, tail and thyroid were also excised. A small length of mesenteric vessel was 
excised and placed on ice for further physiological analysis. A first- or second order 
artery from the mesentery (200-400 μm initial diameter, 2-3 mm in length) from the 
SiNP-injected rat was dissected out using fine forceps and mounted between two 
glass cannulae fixed in place on a modified pressure myography chamber at 60 
mmHg intra-vascular pressure and constantly superfused with gassed PSS at 37oC, 
pH 7.4, as described above. The viability of the mesenteric artery was determined by 
its ability to constrict to KPSS (60 mM KCl). Constrictor responses to Phe (10-9-10-4 
M) was initially assessed, followed by the endothelial-dependent (ACh, 10-13-10-3 M) 
and independent (SNP, 10 and 100 nM; PAPA, 100 μM) dilator responses in Phe-
preconstricted vessels.  
 
2.5. Tissue fixation and transmission electron microscopy 
At the end of the functional studies, vessels were carefully untied from the glass 
cannulae and immediately fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate 
buffer, pH 7.3 over 2 hours at 22oC. The samples were postfixed with reduced 
osmium (OsO4 1% + K4Fe(CN)6 1.5%) for 1 hour, then dehydrated in a series of 
alcohols, infiltrated with TAAB LV resin and polymerised for 24 hours at 60oC, as 
described previously (Akbar et al., 2011). Ultrathin 70 nm sections were cut with 
Leica ‘Ultracut S’ ultramicrotome and placed on copper grids. The grids were 
observed in Tecnai 12 Biotwin transmission electron microscope at 80 kV. 
 
2.6. Determination of SiNP uptake and biodistribution 
Inductively coupled plasma mass spectrometry (ICP-MS; Perkin Elmer, UK) was 
used in order to quantify and calculate the relative amount of the silica (Si) metal in a 
sample containing the ex vivo or in vivo -relevant amount. The sample was diluted in 
5 mL dH2O and subjected to analysis using ICP-MS. Additionally, to verify SiNP 
uptake by vessels and other organs, ICP-MS was used to measure Si concentration. 
Briefly, vessels were weighed and placed into 500 µL lysate buffer solution 
(containing 0.5 g sodium dodecyl sulphate (SDS; Sigma, Japan), 0.29 g NaCl, 0.39 g 
tris, 0.03 g Tris(hydroxylmethyl) and aminomethane, and 250 μL of the protease 
inhibitor cocktail in 25 mL of dH2O) and allowed to digest over 48 hours at room 
temperature. The lysate was subsequently mixed in 1 mL high purity (70%) nitric 
acid in glass tubing and placed in an oil bath at 115oC, for 2-3 hours. The solution 
was made up to 5 mL in distilled water and analysed. A standard curve was used to 
quantify the amount of metal in the tissues, using standards (Sigma, UK), in the 
same background solution as that of the tissue solutions. The lower limit of Si 
quantification was 50 ng/mL. These results were used to quantify the actual 
concentration of SiNPs within solutions in mg/g of animal tissue by considering the 
dilution factor. The uptake concentrations were expressed as mean percentage of 
the actual dose injected (100%). 
 
2.7. Inhibition studies 
A series of inhibition studies were carried out, firstly to characterise the dilator 
component in small mesenteric arteries, followed by co-incubation of vessels with 
SiNPs in the presence of the inhibitors. Ex vivo vessels were mounted as described 
previously and responses to ACh were assessed before and 30 minutes after 
incubation in inhibitors including; Nω-nitro-L-arginine (L-NNA, 100 µM), indomethacin 
(10 µM), apamin (100 nM) and TRAM-34 (1 µM) (potassium channel inhibitors; 
Sigma-Aldrich, Poole, UK). Inhibitors were intraluminally infused into the mesenteric 
artery as well as superfused for 30 minutes. Dilator responses were assessed 30 
minutes after incubation in the inhibitors, in the continued presence of inhibitors 
inside the vascular lumen and in the superfusate. Subsequently, vessels were co-
incubated in both L-NNA and SiNPs (5.32 x 1011 NPs/mL in PSS) for 30 minutes to 
assess the effects on function. In a separate set of experiments, vessels were co-
incubated in SiNPs and superoxide dismutase (SOD), used at 300 U/mL.  
 
2.8. Statistical analysis 
A generalised linear mixed model (GLMM) approach was performed for the statistical 
analysis of the data obtained using the IBM statistical package for social sciences 
(SPSS) version 19.0 (Breslow and Clayton, 1993). The model is an extension of the 
generalised linear model in which the linear predictor contains random effects, in 
addition to the usual fixed effects for sample effects regression analysis of grouped 
data. This model provides an extension of the linear mixed models to non-normal 
data (in our case % response values). This fixed-effects model of analysis of 
variance was applied due to the existence of different parameters or independent 
variables across different sets of experiments that can influence the dependent 
variable. The dependent variable represents the dilator response elicited by ACh and 
SNP which is expressed as percentage relaxation (corresponding to the increase 
from the pre-constricted maximal Phe value), or the constrictor response by Phe. 
The independent variables include: the number of the mesenteric vessel segments 
used, incubation type of the vessels [PSS, SiNPs at high dosage, SiNPs at low 
dosage, SiNPs with L-NNA, SiNPs with SOD, inhibitors (L-NNA, indomethacin, 
apamin and TRAM-34; alone or in combination] and chemical concentration (10
-13
-
10
-3 
M) of the agonist used. As each vessel in this current study was repeatedly 
assessed (before as well as after incubation) for the different agonist concentration, 
the co-variant was also taken into account. The co-variant is the weight of each 
vessel i.e. how many occasions it was measured for either % contraction or 
relaxation. This allowed for the estimation of the ranges of response variable values 
that the independent factors would generate in a particular set of experiments. This 
whole analysis determined two factors, which are the ‘incubation type’ and the 
‘agonist concentration’ to be responsible for the main significant effects contributing 
to the variation in vascular % responses (contraction or relaxation). This justified the 
use of repeated measures (one-, two-, three- or multi-variate) analysis of variance 
(ANOVA) for multiple sample mean comparisons due to the vessels being repeatedly 
measured for their responses to different agonist concentrations. The ANOVA tests 
were performed to specify which incubation type is contributing to the significance of 
results (% response measurements). The pairwise adjustments identified the 
particular dose(s) that lead to the significance of results among the different 
incubation types.  
 
The number of mesenteric vessel segments from different animals are expressed as 
n, represents the number of vessels utilised for each set of experiments (1 vessel 
per animal). Data is represented as mean ± standard error of mean (SEM). 
Concentration response curves were assessed using the appropriate ANOVA test 
with subsequent pairwise comparisons to determine the main effects of dose and 
incubation as well as the interaction of effects. Bonferroni adjustments were used to 
correct for multiple comparisons. If a main effect was observed, Student’s paired or 
unpaired t-test (two tailed) was used to determine the locations of differences as 
appropriate. p<0.05 was considered to be statistically significant. The maximum 
agonist effect (Emax) and concentration inducing 50% of Emax (EC50) were determined 
from each concentration response curve and pD2 was calculated as the -log(EC50). 
Emax and pD2 values were calculated using the GraphPad Prism Software 7. 
 
3. RESULTS 
 
3.1. Characterisation of SiNPs 
Transmission electron microscopy (TEM) and scanning electron microscopy images 
demonstrated the mono-dispersed and spherical morphology of SiNPs with an 
overall size of 97.85 ± 2.26 nm (Figure 1). The Zeta potential measurement of SiNP 
samples in water was -41.0 ± 1.04 mV and that in PSS was -12.0 ± 0.38 mV (Figure 
1). The fluorescence spectra of SiNPs showed a peak obtained at its expected 
wavelength (550-690 nm), confirming the presence of the RBITC dye (Fig 1C). 
 
3.2. Cellular uptake of SiNPs into the mesenteric arteries  
Examination of the TEM sections demonstrates the presence of SiNPs inside ECs of 
the mesenteric vessels after a 30 minute incubation in SiNPs (at 5.32 x 1011 
NPs/mL) at 37oC ex vivo (Figure 2A and B). They were unevenly distributed and 
dispersed throughout the cytoplasm of ECs, but none were found in the nucleus. 
SiNPs were located either singly or in small clusters and were predominantly 
membrane-bound within vesicle structures that may be of endosomal or lysosomal 
origin suggesting that an endocytic pathway of uptake may be involved (Figure 2A 
and B). A greater number of SiNPs were identified inside ECs after exposure to high 
dose vs low dose SiNPs. SiNPs were also identified (but with reduced number in 
comparison to ex vivo exposure), within the cytoplasm of ECs from the in vivo 
injected rats with none being identified in the nucleus, smooth muscle cell layer or 
the adventitia (Figure 2C and D). Uptake of SiNPs into the mesenteric vessels was 
also confirmed by ICP analysis (Section 3.6) 
 
3.3. The influence of SiNPs on vasoconstrictor responses 
All vessels constricted to high potassium salt solution (60 mM KCl). Incubation in 
SiNPs ex vivo, had no overall influence on the contractile responses (the mean 
percentage constriction was 78.49 ± 7.13% vs. 65.80 ± 7.04% after incubation in 
PSS and SiNPs, n=7 and 10 respectively, unpaired t-test, NS; Figure 3A). This 
finding was similar to that obtained in the in vivo injected rats (The mean percentage 
constriction was 78.49 ± 7.13% vs. 71.29 ± 17.39% after incubation in PSS and 
SiNP injection, n=7 and 4 respectively, unpaired t-test, NS; Figure 3A). All vessels 
constricted to Phe, in a dose dependent manner. Incubation in SiNPs ex vivo, at 5.32 
x 1011 NPs/mL, had no effect on the pD2 values for Phe-induced constriction in 
mesenteric arteries despite the significant reduction in the maximal constriction 
responses (For SiNPs incubated ex vivo, at 5.32 x 1011 NPs/mL ; Phe Emax 39.73 ± 
5.40%; pD2 0.22 ± 1.18 µM vs. Emax 96.51 ± 5.90%; pD2 0.51 ± 0.58 µM for control 
responses (p<0.05); Table 1). The incubation in SiNPs ex vivo, at 5.32 x 1011 
NPs/mL, led to a significant reduction in the contractile responses of vessels to Phe, 
at specific concentrations (1, 10 and 100 µM). At 10 µM Phe, the mean percentage 
constriction was 98.55 ± 1.45% vs. 36.51 ± 11.17% after incubation in PSS and 
SiNPs ex vivo, n=4 and 5 respectively, unpaired t-test, p<0.0001; Figure 3B). There 
was no overall change in the Phe constrictor responses in mesenteric arteries after 
ex vivo infusion at the lower dosage of 1.01 x 1011 NPs/mL (Phe Emax 103.60 ± 
3.59%; pD2 0.37 ± 0.29 µM, vs. Emax 96.51 ± 5.90%; pD2 0.51 ± 0.58 µM for control 
responses (p<0.05)Table 1), or after the in vivo injection of SiNPs, as compared to 
control (At 100 nM Phe, the mean percentage constriction was 15.85 ± 4.05% vs. 
19.48 ± 13.57% after incubation in PSS and SiNP injection in vivo, n=4 and 3 
respectively, unpaired t-test, NS; Figure 3B).  
 
3.4. The influence of SiNPs on vasodilator responses; Endothelial-dependent 
(ACh) Responses 
All pre-constricted vessels dilated to ACh in a dose dependent manner. Incubation in 
SiNPs ex vivo, at 1.01 x 1011 NPs/mL (lower dosage) had no overall detrimental 
influence on ACh responses (Figure 4). However, exposure to SiNPs at 5.32 x 1011 
NPs/mL (higher dose), ex vivo led to a significant attenuation in the dilator responses 
to ACh following Phe pre-constriction, at specific concentrations (100 nM to 1 mM) 
(Figure 4). At 1 µM of ACh, the mean percentage dilation was 96.15 ± 3.11%, 27.82 
± 5.13% after incubation in PSS and SiNPs respectively (n=6 and 11 respectively, 
unpaired t-test, p<0.001; Figure 4). There was a significant rightward shift in the 
concentration-response curve and reduced the maximal dilation to ACh (ACh Emax 
43.67 ± 4.33%; pD2 1.14 ± 8.66 µM, vs Emax 97.03 ± 3.38%; pD2 0.02 ± 0.04 µM for 
control responses (p<0.05); Table 1). When infused under flow conditions ex vivo (at 
a final dosage of 5.32 x 1011 NPs/mL) SiNPs had no overall effect on the magnitude 
of dilator responses at higher concentrations of ACh following Phe pre-constriction 
(1–100 µM of ACh); but led to a significant decrease in the magnitude of dilator 
responses at ACh concentration of 100 nM (Figure 4). Although the incubation in 
SiNPs at the lower dosage and under flow conditions produced a rightward shift in 
pD2, the maximal dilation levels were unaffected (Table 1). 
 
In contrast, injection of SiNPs in vivo, at a final dosage of 5.32 x 1011 NPs/mL, had 
no overall effect on the magnitude of dilator responses at high concentrations of ACh 
following Phe pre-constriction of mesenteric arteries (1-100 µM of ACh; Figure 4). In 
vivo injected SiNPs produced a significant reduction in the magnitude of ACh-
induced dilation only at lower concentrations of ACh (10 and 100 nM; similar to ex 
vivo) following Phe pre-constriction of mesenteric arteries (Figure 4), with a right 
ward shift in pD2 (Table 1).  Hence, the infusion of SiNPs under flow conditions and 
their injection in vivo displayed less detrimental effect on vasodilator responses 
compared to ex vivo exposure under static conditions. 
 
3.5. The influence of SiNPs on vasodilator responses; Endothelial-
independent responses 
The endothelial-independent dilator responses to the NO donor, SNP were 
unaffected by incubation in SiNPs at 5.32 x 1011 NPs/mL at SNP concentrations of 
10 and 100 nM (At 10 nM ACh, the mean percentage dilation was 79.44 ± 6.52% vs. 
60.56 ± 18.51% after incubation in PSS and SiNPs, ex vivo, n=4 and 6 respectively, 
unpaired t-test, NS; Figure 5A). In contrast, SNP responses were significantly 
affected by SiNPs that were injected in vivo at specific SNP concentrations (10 and 
100 nM) (At 10 nM concentration of SNP, the mean percentage dilation was 79.44 ± 
6.52% vs. 2.80 ± 2.14% after incubation in PSS and SiNP injected in vivo, n=4 and 3 
respectively, unpaired t-test, p<0.001; Figure 5A). The maximal concentration of 
SNP also displayed a significant reduction in dilation in SiNP-injected rats (At 100 
nM concentration of SNP, the mean percentage dilation was 99.31 ± 5.72% vs. 
15.21 ± 13.40% after incubation in PSS and SiNP injected in vivo, n=4 and 3 
respectively, unpaired t-test, p<0.001; Figure 5A). The dilator responses to an 
endothelial-independent smooth muscle cell relaxant (PAPA; at 100 µM) were 
unaffected by the infusion of SiNPs ex vivo (At 100 µM concentration of PAPA, the 
mean percentage dilation was 89.04 ± 12.53% vs. 105.07 ± 2.79% after incubation in 
PSS and SiNPs respectively, n=3, unpaired t-test, NS; Figure 5B). Likewise, the 
vasodilator responses to PAPA were unaffected by SiNP injection in vivo (At 100 µM 
concentration of PAPA, the mean percentage dilation was 89.04 ± 12.53% vs. 
104.53 ± 4.32% after incubation in PSS and SiNPs respectively, n=3, paired t-test, 
NS; Figure 5B).  
 
3.6. SiNP biodistribution within tissues and organs 
The ICP elemental analysis confirmed the internalisation of SiNPs within various 
tissues and organs after their injection in vivo (Figure 6). A small fraction of 5.6 ± 
2.56% of the SiNPs (5.60 x 10-4 ± 2.56 x 10-4 mg/g of animal tissue) administered in 
vivo were localised within various tissues including; lungs, heart, aorta, mesentery, 
liver, spleen and kidney (Figure 6). Despite the minimal concentration of SiNPs 
internalised into different tissues, the largest fraction of uptake was observed within 
the mesenteric arterial tissue with the latter accounting for nearly 5% of the SiNPs 
injected in vivo (Figure 6). 
 
3.7. The molecular mechanisms of SiNPs-induced attenuated dilation 
Findings from the present study suggest that exposure of small mesenteric arteries 
to SiNPs at the higher dosage under static conditions, over a 30 minute acute period, 
has a detrimental effect on endothelial-dependent (ACh) dilator responses. In order 
to elucidate the mechanisms involved, a series of experiments were conducted 
including; the characterisation of the dilator component in the absence and presence 
of SiNPs and examination of the effect of co-incubation with superoxide dismutase (a 
reactive oxygen species [ROS] scavenger). We examined two theories concerning 1) 
the involvement of ROS in mediating SiNP-induced impairment of vascular function 
and 2) the influence of SiNPs on vasodilator pathways, by using specific dilator 
pathway inhibitors (L-NNA, Indomethacin, as well as apamin and TRAM-34 which 
are small and intermediate potassium channel inhibitors, respectively, used to inhibit 
the EDHF pathway).   
 
In control vessels, the inhibition of nitric oxide synthesis (using L-NNA) ex vivo had 
no overall effect on the ACh-induced dilator responses in Phe pre-constricted 
vessels (Figure 7A). This is despite a significant decrease in dilation to ACh at 10 
nM (the mean percentage dilation was 39.30 ± 11.25% vs. 8.78 ± 4.86% after 
incubation in PSS and L-NNA respectively, n=6, paired t-test, p<0.05; Figure 7A), 
while at 1 nM, submaximal (100 nM) and higher (1 µM and 10 µM) ACh 
concentrations, dilations were preserved (Figure 7A). Incubation in the SKCa and 
IKCa channel-selective inhibitors; apamin (at 100 nM) and TRAM-34 (at 1 µM), 
respectively, produced a significant rightward shift in the concentration-response 
curve, without affecting the maximal relaxation to ACh (ACh Emax 106.20 ± 3.58%; 
pD2 0.27 ± 0.24 µM for apamin (p<0.05, n=4); Emax 99.37 ± 2.79%; pD2 0.27 ± 0.18 
µM for TRAM-34 (p<0.05, n=4) vs. Emax 97.03 ± 3.38%; pD2 0.02 ± 0.04 µM for 
control responses (n=6), respectively; Table 1). However, when the apamin was 
added in combination with TRAM-34, this produced a further rightward shift in the 
concentration-response curve and reduced the maximal relaxation (For apamin and 
TRAM-34; ACh Emax 19.78 ± 4.16%; pD2 31.19 ± 7.20 µM, p<0.01, n=4; Table 1). 
The co-incubation of mesenteric arteries in apamin and TRAM-34 significantly 
reduced and almost abolished the vasodilator responses to ACh, with this being 
further reduced when an inhibitor cocktail containing L-NNA, apamin and TRAM-34 
was added (Figure 7A). To investigate whether a NO-independent pathway was 
involved in mediating the small degree of dilation that is present following the 
inhibition in L-NNA, apamin and TRAM-34, we used a cyclooxygenase inhibitor; 
indomethacin. The inhibition of the COX with indomethacin had no overall effect on 
the ACh-induced dilator responses in Phe pre-constricted vessels; (At 100 nM ACh, 
the mean percentage dilation was 78.77 ± 8.58% vs. 84.41 ± 10.97%  after 
incubation in PSS and indomethacin, n=6 and 4 respectively, unpaired t test, p<0.05; 
Figure 7A). The incubation in the inhibitor cocktail containing L-NNA, apamin + 
TRAM-34 or L-NNA, indomethacin, apamin and TRAM-34 abolished the vasodilator 
responses to ACh (For all inhibitors; ACh Emax 0.63 ± 0.33%; pD2 1.52 x 103 ± 1.45 x 
103, p<0.001, n=5; Table 1 and Figure 7A).   
 
There was a significant rightward shift in the concentration-response curve with 
reduced maximal dilation to ACh The co-incubation of SiNPs in the presence of L-
NNA completely abolished the dilator responses to ACh at all concentrations tested 
(Figure 7B). The most drastic effects were observed at the submaximal (100 nM), 
maximal (1 µM) and highest (10 µM) ACh concentrations (At 100 nM ACh, the mean 
percentage dilation was 78.77 ± 8.58% vs. 3.09 ± 1.48% after incubation in PSS and 
SiNPs with L-NNA respectively, n=6 and 7 respectively, unpaired t test, p<0.001; 
Figure 7B). (ACh Emax 3.34 ± 0.77%; pD2 23.99 x 103 ± 0.74 x 103 µM, p<0.0001, 
n=7; Table 1). 
 
When vessels were co-incubated in SiNPs (5.32 x 1011 NPs/mL) and superoxide 
dismutase (SOD) dilation of Phe pre-constricted vessels was not restored but led to 
further reduction in the ACh dilator responses, especially at the highest ACh 
concentration (At 10 µM ACh, the mean percentage dilation was 96.68 ± 7.82% vs. 
35.58 ± 3.51% after incubation in PSS and SiNPs with SOD respectively, n=6 and 5 
respectively, unpaired t-test, p<0.001; Figure 7B). 
 
 
 
4. DISCUSSION 
In the present study, we demonstrate that SiNPs can influence the functional 
responses of small mesenteric arteries after acute exposure, ex vivo, and after iv 
administration in vivo. Using our ex vivo model, we show that these effects are dose 
dependent but are less detrimental after exposure under flow vs static conditions. 
Using pharmacological inhibition studies, our findings suggest that SiNPs may 
interfere with the EDHF vasodilator pathway. 
The acute exposure of vessels to SiNPs led to their cellular uptake into the 
cytoplasm of ECs, either being freely localised or inside vesicles, without affecting 
cellular integrity. Some SiNPs seemed to form aggregates near the surface of ECs 
and were seen inside vesicle structures near the outer edges of the cell. This was 
evident ex vivo under static and flow conditions and after in vivo exposure, though 
there were less SiNPs taken up by ECs in vivo. Under flow conditions, ex vivo, many 
nanoparticles were seen outside the cell.  Due to the predominant negative charge 
on the SiNPs at physiological pH, this may have caused their repulsion from EC 
surfaces, perhaps via their negative membrane phospholipidic groups (Gamucci et 
al., 2014). We assume that SiNPs have either become neutralised or gained positive 
charge or both by the ionic species found in PSS and/or ECs secretions, ECM 
proteins in vivo, forming a protein corona (Gamucci et al., 2014). The internalisation 
of SiNPs by ECs has previously been documented both in vitro and in vivo. Barbé et 
al. reported the internalisation and passage of SiNPs through small intercellular 
openings in normal blood vessel walls in vivo (Barbé et al., 2004), while Kasper et al. 
found that amorphous SiNPs (30, 70 and 300 nm) at 2 x 1011 NPs/mL were localised 
within human microvascular ECs, inside specialised flotillin-1- and flotillin-2-bearing 
endocytic vesicles (Kasper et al., 2013). The uptake of SiNPs may largely be related 
to an engulfment through the endocytosis pathway.  
While acute exposure to SiNPs ex vivo had no overall influence on contractile 
responses to high potassium solution, we show that SiNPs can significantly reduce 
Phe-induced constrictor responses of mesenteric arteries, at maximal Phe 
concentrations. Phe acts via α1-adrenoceptors located on the membrane surface of 
the vascular smooth muscle cells (VSMCs) to activate a Ca2+-dependent sensitising 
pathway during the sustained late-phase contraction (Kitazawa and Kitazawa, 2012). 
The action of Phe is mediated via protein kinase C (PKC) leading to the 
phosphorylation and inhibition of myosin light chain phosphatase and subsequent 
sacroplasmic Ca2+ release and voltage-dependent Ca2+ influx (Kitazawa and 
Kitazawa, 2012). The compromise of the Phe-induced constriction and the 
unsustained constriction of the vessels at maximal Phe doses after SiNP exposure 
ex vivo may be due to a number of reasons, including the random blockage of Phe 
receptor, acting as a non-competitive antagonist as indicated by the reduced Emax 
and pD2 values, and/or the enzymes, mediators and adaptor proteins involved in 
mediating the action of Phe. SiNPs injected in vivo, had no overall effect on Phe-
induced contraction (at the higher doses) contrary to the results found after ex vivo 
infusion of SiNPs. This may be due to the corona formation after the SiNPs are 
injected into the blood (Tenzer et al., 2011), thus preventing their interaction with the 
α1-adrenergic receptors. The ability of PAPA to induce relaxation of VSMCs after the 
in vivo SiNP injection (attributed to its direct action on the smooth muscle cell layer) 
suggests that SiNPs had no overall effect on the contractile machinery, or the 
integrity of the VSMCs. Another plausible reason for the reduced Phe constriction 
may relate to the possibility that SiNPs may interfere with the action of potassium 
channels. A direct influence of nanoparticles on potassium channels has recently 
been documented. Soloviev et al (2015) used a whole cell patch clamping technique 
to demonstrate potassium channel activation (large conductance, BKCa, which are 
found on the surface of VSMCs) by gold nanoparticles. Addition of gold 
nanoparticles to whole isolated aortic vessels led to a decrease in the amplitude of 
Norepinephrine induced contractions, in a concentration dependent manner 
(Soloviev et al, 2015).  
 
Acute exposure to SiNPs under static conditions (at the higher dosage) significantly 
reduced ACh-induced dilation of mesenteric vessels ex vivo. Although SiNPs 
injected in vivo, induced significant reduction in dilator responses at the lower ACh 
doses, there was no overall detrimental reduction in dilation at higher ACh doses. 
This may relate to corona formation after the nanoparticles are injected into the 
animal (Tenzer et al, 2011). A recent study by Nemmar et al. suggested a significant 
reduction in the endothelium-dependent relaxation (at ACh concentration of 0.1 µM) 
of small rat mesenteric arteries (third-branches) following exposure to amorphous 
SiNPs (of 50 and 500 nm size respectively, at 50 µg/mL) ex vivo, using the wire 
myography system (Nemmar et al., 2014). Previous findings from our group, using 
large aortic vessels, also demonstrate that SiNPs have a direct influence on dilator 
function. While acute exposure to 100 and 200 nm nonmodified SiNPs (at 1.1 × 1011 
NPs/mL) had no detrimental effect on conduit arterial function, the positively charged 
SiNPs had a greater degree of attenuation on dilator responses (Akbar et al., 2011). 
Furthermore, using 30 and 70 nm SiNPs, we demonstrate that attenuation of 
endothelial-dependent vasodilator responses is related to nanoparticle surface area 
rather than size (Farooq et al., 2013). In the present study, we show that the 
attenuation in endothelial-dependent dilation ex vivo, is dosage dependent. This may 
relate to the number of nanoparticles being taken up by the lining ECs, however, it is 
recognised that SiNPs do not need to be internalised to affect vascular function, 
possibly interacting with cell surface receptors and channel proteins (Soloviev et al, 
2015; Yan et al, 2013). 
 
The SiNP surface has previously been shown to generate ROS, that could quench 
nitric oxide hence affecting vasodilation (Farooq et al., 2013) and/or cause 
nitroxidative/oxidative stress (Corbalan et al., 2011). Previous studies have reported 
effects of SiNPs on inducing EC dysfunction through oxidative stress via JNK-, p53- 
and NF-κβ-related pathways (Liu and Sun, 2010) or the induction of antioxidant 
enzymes (catalase, glutathione transferase and thioredoxin reductase) by 100 nm 
SiNPs through ROS-dependent pathways (Passagne et al., 2012). Furthermore; an 
impairment of EDHF-related vasodilation in the mesenteric arteries of the rat via 
ROS-dependent mechanism has also been suggested previously (Zhao et al., 2013). 
The co-incubation of vessels in SiNPs and SOD did not restore vasodilation, as we 
have previously demonstrated with large vessels (Farooq et al., 2013), suggesting 
that the mechanism for SiNP impairment of vasodilation is ROS-independent and 
may involve alternative mechanisms.  
 
Our inhibition studies demonstrate that in control Phe-preconstricted vessels, the 
vasodilator response was influenced by all inhibitors tested, thus demonstrating that 
both nitric oxide and EDHF contribute to the vasodilator component in mesenteric 
arteries. Therefore, the incubation of mesenteric arteries in L-NNA may have partially 
compromised vasodilation as a result of reduced nitric oxide bioavailability (Joshi 
and Woodman, 2012). The co-incubation of SiNPs in the presence of L-NNA 
completely abolished the dilator responses to ACh. This suggests that SiNPs may 
directly affect the EDHF pathway. The more pronounced role of EDHF in small 
mesenteric arteries (specifically second to fourth order arteries) compared with 
medium sized and large conduit arteries such as the superior mesenteric artery and 
the aorta is attributed to the action of intermediate- and small-conductance Ca2+-
activated potassium channels in ACh-induced relaxations (Hilgers et al., 2006). The 
dilation of mesenteric arteries in the presence of the inhibitor cocktail (L-NNA, 
apamin and TRAM-34) was not sufficient to completely abolish the dilator response 
of the mesenteric arteries and was able to maintain a very minimal dilation which 
may be due to the contribution of prostanoids (Honing et al., 2000) from the 
cyclooxygenase pathway. Previous reports also suggest the participation of 
connexins in mediating the endothelial-dependent hyperpolarisation via 
myoendothelial gap junctions in different vascular beds (de Wit and Griffith, 2010). 
These gap junctions may have alternative potassium channels to the apamin/TRAM-
34-sensitive calcium-activated potassium (K+) ones and/or rely on other pathways 
that lead to vasodilation including cAMP (Chaytor et al., 2002). Consequently, the 
attenuation in dilation may be due to 1) the indirect or the direct interaction of SiNPs 
with specific extracellular, intracellular and downstream factors involved in the 
EDHF-dependent pathway in ECs and 2) the inability of nitric oxide to compensate 
for the loss in EDHF action due to the delayed nitric oxide production and/or the 
influence of SiNPs on eNOS or other factors involved in nitric oxide synthesis and 
action, as has been demonstrated after TiO2 NP inhalation, which caused disruption 
in nitric oxide signalling and resultant blunted arteriolar dilation (Nurkiewicz et al., 
2009, LeBlanc et al., 2009). Additionally, the effect of SiNPs on EC function may be 
related to the interaction, disruption and/or blockage of muscarinic (M)-3 ACh 
receptors on the EC surface, voltage-gated channels, and/or trafficking and transport 
of the vasodilator machinery. Our findings are further supported by evidence 
suggesting that cardiovascular toxicity triggered by SiNPs occurs mainly in vascular 
endothelium rather than cardiomyocytes, where the SiNPs induced damage to 
cytoskeletal organisation, attenuating expression of cellular adhesion molecules and 
contributing to disturbance of EC homeostasis and influence on 
VEGF2/MAPK/Erk1/2/mTOR signalling pathways (Duan et al., 2014). Nanoparticles 
have also been shown to alter the activity of potassium channels. Although there is a 
lack of understanding of the direct influence of SiNPs on potassium channels within 
ECs, one study has demonstrated that treatment of HUVECs with SiNPs (~50 nm 
diameter), in vitro, led to a decrease in cell survival rate, increased inflammatory 
cytokines and increased the potassium channel activity in the opening rate and 
current intensity (Yang et al, 2013).  
 
The ex vivo exposure to SiNPs had no influence on the NO-independent dilator 
pathway for mesenteric vessels indicating that smooth muscle sensitivity to NO was 
unaffected. This finding was supported by other studies from our group, in large 
vessels described earlier. In contrast, the in vivo injected SiNPs induced a significant 
reduction in SNP induced dilation, as we have previously demonstrated for the QDs 
(Shukur et al., 2013). The mechanism for this is unclear, however, it is noteworthy 
that ingestion of silica over an 8 day period has been documented to modify the 
characteristics of endothelial dilation in rat aorta, with signification reduction in the 
SNP induced dilation and attenuation of SMC responsiveness to nitric oxide (Oner et 
al, 2006). This has important medical implications on SNP-based drugs used in 
cardiovascular disease patients.   
 A comparison between ex vivo and in vivo findings suggest that while under static 
conditions SiNPs attenuate endothelial dependent dilation, when introduced under 
flow conditions ex vivo, responses were similar to those after their in vivo injection. In 
vivo, the injected SiNPs are likely to adsorb proteins from the serum, forming a 
‘corona’ thus altering surface characteristics of the SiNPs, which may lead to 
reduced uptake by the lining ECs, in comparison to uptake ex vivo (Ang et al., 2014). 
Whilst these effects may relate to the number of nanoparticles being taken up by 
ECs, the influence of cyclic stretch on the uptake and cytotoxicity has been 
controversial. In one study, culturing human umbilical vein ECs under physiological 
cyclic stretch conditions did not show enhanced uptake and/or increased cytotoxicity 
of amorphous SiNPs when compared to static culture conditions (Freese et al., 
2014).  In contrast, Hu and Liu (2015) have demonstrated enhanced cellular uptake 
of 100 nm polystyrene nanoparticles under cyclic stretch using bovine aortic 
endothelial cells (relevant to physiological strain levels) (Hu and Liu, 2015).The 
uptake of SiNPs by ECs was also confirmed by ICP analysis demonstrating that 
SiNPs had largely accumulated in mesenteric arteries in vivo. The mesentery 
represents the highest proportion of ECs, in comparison to other tissues e.g. the 
heart. A similar in vivo study by Borak et al. found that only 36% of the introduced 
SiNPs (150 nm) were excreted after four days of iv injection, suggesting a longer 
term retention of these nanoparticles by tissues (Borak et al., 2012). The dosage of 
SiNps used in our in vivo study is comparable to that used by other biocompatibility 
and biodistrinution studies. Ivanov et al. (20??), used, SiNPs (10 and 13 nm) at a 
dosage of 7 mg/Kg to assess their hematological and biochemical parameters in rats 
5, 21 and 60 days after intravenous administration. The study by Lee et al. injected 
16 mg/Kg of mesoporous SiNPs with an average size of 50–100 nm for in vivo 
optical imaging. A similar dosage of 20 mg/Kg of SiNPs was also injected into mice 
to study their in vivo biodistribution and pharmacokinetics (Yu et al, year ??). 
-  
 
5. CONCLUSION 
In conclusion, we demonstrate that exposure to SiNPs (infused intralumenally or 
injected intravenously), can alter physiological function of rat mesenteric vessels, 
depending on nanoparticle dosage. In the present study, an attempt was made to 
elucidate the mechanism of attenuated endothelial dependent dilator responses by 
SiNP uptake, using inhibition studies. The compromise in dilator responses ex vivo 
may be attributed to SiNP effects on the EDHF related vasodilator pathway. Our 
findings highlight the importance of assessing the biosafety of nanoparticles for use 
in imaging diagnostics and medical interventions in order to minimise their 
toxicological influence on vessel contractility and function.  
 
 
6. Summary points: 
 
1. Mono-dispersed dye-encapsulated silica nanoparticles [SiNPs] (97.85 ± 2.26 
nm diameter) were fabricated and characterised and their influence on small 
mesenteric arterial function assessed ex vivo, under static and flow 
conditions. The influence of intravenous injection of SiNPs, in vivo, was also 
assessed.  
2. The technique of pressure myography was used to assess the vasoconstrictor 
(phenylephrine [Phe]) and endothelial-dependent (acetylcholine [ACh]) and 
independent (sodium nitroprusside [SNP]) vasodilator responses of small 
mesenteric arteries, from male Wistar rats, before and after acute exposure to 
the SiNPs. 
3. SiNPs were rapidly taken up by ECs lining mesenteric arteries. SiNPs 
attenuated Phe contractile responses, but did not alter the responses to KPSS 
or papaverine ex vivo, suggesting that the contractile machinery is unaffected 
by SiNP uptake.  
4. Exposure of mesenteric arteries to SiNPs, ex vivo, under static conditions, led 
to an attenuation in endothelium dependent (ACh) dilator responses (at 5.32 
x1011 NP/mL), however, at a lower SiNP dose (1.01 x 1011 NPs/mL) there was 
no overall effect on ACh responses. The endothelium-independent (SNP) 
vasodilator responses were unaffected by incubation in SiNPs.  
5. The compromise in dilator responses shown after ex vivo exposure at the 
higher SiNP dosage, may be attributed to SiNP effects on the EDHF-related 
pathway as demonstrated by our inhibition studies. 
6. When injected intravenously in vivo, SiNPs only had a detrimental effect on 
constrictor (Phe) and endothelial dependent (ACh) dilator responses, at the 
lower agonist concentrations, similar to SiNP effects when infused under flow 
conditions.  
7. A significant reduction in SNP-induced dilator responses was seen after 
SiNPs were injected in vivo. This may have clinical implications on the use of 
SNP drugs for patients with cardiovascular disease.  
8. The dosage dependent influence of SiNPs on arterial function will help identify 
strategies for their safe clinical administration in the future. 
9. Our findings highlight the importance of assessing the biosafety of 
nanoparticles for use in imaging diagnostics and medical interventions in 
order to minimise their toxicological influence on vessel contractility and 
function. 
 
 
  
Figure legends 
 
Graphical Abstract. A schematic illustration summarising the effect of SiNPs on the 
vasodilator function of ECs and VSMCs of the mesenteric artery and the potential 
associated mechanisms involved in mediating their behaviour ex vivo. AA; 
arachidonic acid, ACh; acetylcholine, BKCa; large-conductance calcium-activated 
potassium channels, Ca2+; calcium ion, cAMP; cyclic AMP, cGMP; cyclic guanosine 
monophosphate, COX-2; cyclooxygenase-2, CREB; response element-binding 
protein, Cx 40; connexion 40, CYP; cytochrome P450, EDHF; endothelial-derived 
hyperpolarising factor (EDHF), EET; epoxyeicosatrienoic acid, eNOS3; endothelial-
derived NO synthase 3 isotype, ERK; Extracellular-signal-regulated kinase, GC; 
guanylyl cyclase, Gp; G protein, GTP; guanosine-5‘ triphosphate, IKCa; intermediate-
conductance calcium-activated potassium channels, IL6; interleukin 6, IL8; 
interleukin 8, K+; potassium ion, Kv; voltage-gated potassium channels, M3; 
muscarinic receptor type 3, MKP-1; mitogen-activated protein (MAP) kinase 
phosphatase-1, NF-κβ; nuclear factor kappa beta, NO; nitric oxide, PKA; protein 
kinase A, PKG; protein kinase G, PLA2; phospholipase A2, PLC; phospholipase C, 
R; receptor, SiNPs; silica nanoparticles, SKCa; small-conductance calcium-activated 
potassium channels, SOD; superoxide dismutase, TNFα; tumor necrosis factor 
alpha, TRP; transient receptor potential.  
 
Figure 1. The Zeta potential output of the silica nanoparticles [SiNPs] (in water; A), a 
scanning electron micrograph of SiNPs with 97.85 ± 2.26 nm diameter (B; scale bar 
=100 nm) and fluorescence spectroscopy of the RBITC dye encapsulated SiNPs (C). 
 
Figure 2. Transmission electron micrographs (A, B, C and D; scale bars = 1 µm, 100 
nm, 0.5 µm and 200 nm, respectively) illustrating the internalisation of SiNPs into the 
vascular endothelium of the mesenteric arteries after incubation, ex vivo (A and B) 
and in vivo (C and D), respectively. The SiNPs are represented by black spherical 
structures inside ECs (arrows).  
 
Figure 3. The influence of SiNPs injected ex vivo vs. in vivo, on the KPSS- (A) and 
Phe- (B) induced contraction. ‘n’ is number of vessels. Multi-variate repeated 
measures ANOVA. *p<0.05, ***p<0.001 and ****p<0.0001, error bars=SEM. P values 
correspond to comparisons between SiNPs incubated either ex vivo or in vivo vs. 
control Phe responses of mesenteric arteries.  
 
Figure 4. The influence of SiNPs injected ex vivo vs. in vivo, on the ACh-induced 
relaxation in Phe pre-constricted vessels. ‘n’ is number of vessels. *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001, error bars=SEM. Multi-variate repeated 
measures ANOVA. P values correspond to comparisons between SiNPs incubated 
either ex vivo or in vivo vs. control responses of mesenteric arteries. 
 
Figure 5. The influence of SiNPs injected ex vivo vs. in vivo, on the SNP- (A) and 
PAPA- (B) induced relaxation in Phe pre-constricted vessels. ‘n’ is number of vessel. 
***p<0.001, error bars=SEM. Multi-variate repeated measures ANOVA. P values 
correspond to comparisons between SiNPs incubated either ex vivo or in vivo vs. 
control responses of mesenteric arteries.  
 
Figure 6. The mean normalised percentage of Silica concentration present in in vivo 
tissues, expressed as a mean percentage of the actual dose injected (100%).  
 
Figure 7. The influence of the inhibitor cocktail of L-NNA, apamin and TRAM-34 as 
well as indomethacin (A) and the co-incubation in SiNPs and L-NNA or SiNPs and 
SOD (B) on the ACh-induced relaxation in Phe pre-constricted vessels. ‘n’ is number 
of vessels. ***p<0.001 and ****p<0.0001, error bars=SEM. Multi-variate repeated 
measures ANOVA. P values correspond to comparisons between inhibitor-incubated 
vs. control ACh responses of mesenteric arteries.  
 
Table 1. The influence of SiNPs and inhibitor incubation on vasoconstrictor and 
vasodilator responses of rat mesenteric arteries. Emax indicates maximal percentage 
response (contraction by Phe or relaxation by ACh or SNP respectively); pD2 values 
represent the –log (EC50), concentration that produced half-maximal responses. 
Values are mean ± SEM. ‘n’ is number of vessels.   
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